ID   TPOR_HUMAN              Reviewed;         635 AA.
AC   P40238; Q5JUZ0;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   28-JUN-2023, entry version 215.
DE   RecName: Full=Thrombopoietin receptor;
DE            Short=TPO-R;
DE   AltName: Full=Myeloproliferative leukemia protein;
DE   AltName: Full=Proto-oncogene c-Mpl;
DE   AltName: CD_antigen=CD110;
DE   Flags: Precursor;
GN   Name=MPL; Synonyms=TPOR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=1608974; DOI=10.1073/pnas.89.12.5640;
RA   Vigon I., Mornon J.-P., Cocault L., Mitjavila M.-T., Tambourin P.,
RA   Gisselbrecht S., Souyri M.;
RT   "Molecular cloning and characterization of MPL, the human homolog of the v-
RT   mpl oncogene: identification of a member of the hematopoietic growth factor
RT   receptor superfamily.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5640-5644(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORMS 1 AND 2).
RX   PubMed=8020956; DOI=10.1006/geno.1994.1120;
RA   Mignotte V., Vigon I., Boucher de Crevecoeur E., Romeo P.-H.,
RA   Lemarchandel V., Chretien S.;
RT   "Structure and transcription of the human c-mpl gene (MPL).";
RL   Genomics 20:5-12(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   UBIQUITINATION AT LYS-553 AND LYS573.
RX   PubMed=19880496; DOI=10.1182/blood-2009-06-227033;
RA   Saur S.J., Sangkhae V., Geddis A.E., Kaushansky K., Hitchcock I.S.;
RT   "Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.";
RL   Blood 115:1254-1263(2010).
RN   [6]
RP   VARIANTS VAL-58 AND LYS-168.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [7]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [8]
RP   INTERACTION WITH ATXN2L.
RX   PubMed=11784712; DOI=10.1074/jbc.m105970200;
RA   Meunier C.F., Bordereaux D., Porteu F., Gisselbrecht S., Chretien S.,
RA   Courtois G.;
RT   "Cloning and characterization of a family of proteins associated with
RT   Mpl.";
RL   J. Biol. Chem. 277:9139-9147(2002).
RN   [9]
RP   VARIANT THCYT2 ASN-505.
RX   PubMed=14764528; DOI=10.1182/blood-2003-10-3471;
RA   Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A.,
RA   Tsuboi K., Nitta M., Miyazaki H., Iida S., Ueda R.;
RT   "Familial essential thrombocythemia associated with a dominant-positive
RT   activating mutation of the c-MPL gene, which encodes for the receptor for
RT   thrombopoietin.";
RL   Blood 103:4198-4200(2004).
RN   [10]
RP   VARIANT ASN-39, AND CHARACTERIZATION OF VARIANT ASN-39.
RX   PubMed=15269348; DOI=10.1073/pnas.0404241101;
RA   Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R.,
RA   Ingersoll R.G., Spivak J.L.;
RT   "Mpl Baltimore: a thrombopoietin receptor polymorphism associated with
RT   thrombocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:11444-11447(2004).
RN   [11]
RP   VARIANT MMM LYS-515.
RX   PubMed=16868251; DOI=10.1182/blood-2006-04-018879;
RA   Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M.,
RA   Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F.,
RA   Litzow M.R., Gilliland D.G., Tefferi A.;
RT   "MPL515 mutations in myeloproliferative and other myeloid disorders: a
RT   study of 1182 patients.";
RL   Blood 108:3472-3476(2006).
RN   [12]
RP   VARIANTS CAMT CYS-102; PRO-102; SER-104; LEU-136; ARG-154; LEU-257;
RP   THR-275; CYS-435 AND TRP-594.
RX   PubMed=16470591; DOI=10.1002/humu.9415;
RA   Germeshausen M., Ballmaier M., Welte K.;
RT   "MPL mutations in 23 patients suffering from congenital amegakaryocytic
RT   thrombocytopenia: the type of mutation predicts the course of the
RT   disease.";
RL   Hum. Mutat. 27:296-296(2006).
RN   [13]
RP   VARIANT MMM LEU-515, AND CHARACTERIZATION OF VARIANT MMM LEU-515.
RX   PubMed=16834459; DOI=10.1371/journal.pmed.0030270;
RA   Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M.,
RA   Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J.,
RA   Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L.;
RT   "MPLW515L is a novel somatic activating mutation in myelofibrosis with
RT   myeloid metaplasia.";
RL   PLoS Med. 3:E270-E270(2006).
RN   [14]
RP   CHARACTERIZATION OF VARIANT THCYT2 ASN-505.
RX   PubMed=19483125; DOI=10.1182/blood-2008-04-149047;
RA   Ding J., Komatsu H., Iida S., Yano H., Kusumoto S., Inagaki A., Mori F.,
RA   Ri M., Ito A., Wakita A., Ishida T., Nitta M., Ueda R.;
RT   "The Asn505 mutation of the c-MPL gene, which causes familial essential
RT   thrombocythemia, induces autonomous homodimerization of the c-Mpl protein
RT   due to strong amino acid polarity.";
RL   Blood 114:3325-3328(2009).
RN   [15]
RP   VARIANT THCYT2 LEU-515.
RX   PubMed=23441089; DOI=10.1002/pbc.24500;
RA   Farruggia P., D'Angelo P., La Rosa M., Scibetta N., Santangelo G.,
RA   Lo Bello A., Duner E., Randi M.L., Putti M.C., Santoro A.;
RT   "MPL W515L mutation in pediatric essential thrombocythemia.";
RL   Pediatr. Blood Cancer 60:E52-E54(2013).
RN   [16]
RP   VARIANT THCYT2 LEU-106, CHARACTERIZATION OF VARIANT THCYT2 LEU-106,
RP   CHARACTERIZATION OF VARIANTS CAMT PRO-102 AND SER-104, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=25538044; DOI=10.1182/blood-2014-07-587170;
RA   Stockklausner C., Klotter A.C., Dickemann N., Kuhlee I.N., Duffert C.M.,
RA   Kerber C., Gehring N.H., Kulozik A.E.;
RT   "The thrombopoietin receptor P106L mutation functionally separates receptor
RT   signaling activity from thrombopoietin homeostasis.";
RL   Blood 125:1159-1169(2015).
CC   -!- FUNCTION: Receptor for thrombopoietin that acts as a primary regulator
CC       of megakaryopoiesis and platelet production. May represent a regulatory
CC       molecule specific for TPO-R-dependent immune responses.
CC       {ECO:0000250|UniProtKB:Q08351}.
CC   -!- SUBUNIT: Homodimer (PubMed:25538044). Interacts with ATXN2L.
CC       {ECO:0000269|PubMed:11784712, ECO:0000303|PubMed:25538044}.
CC   -!- INTERACTION:
CC       P40238; O60674: JAK2; NbExp=6; IntAct=EBI-6511486, EBI-518647;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25538044};
CC       Single-pass type I membrane protein. Golgi apparatus
CC       {ECO:0000269|PubMed:25538044}. Cell surface
CC       {ECO:0000269|PubMed:25538044}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=C-mpl-P;
CC         IsoId=P40238-1; Sequence=Displayed;
CC       Name=2; Synonyms=C-mpl-K;
CC         IsoId=P40238-2; Sequence=VSP_001734, VSP_001735;
CC   -!- TISSUE SPECIFICITY: Expressed at a low level in a large number of cells
CC       of hematopoietic origin. Isoform 1 and isoform 2 are always found to be
CC       coexpressed.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- PTM: Ubiquitination at Lys-553 and Lys-573 targets MPL for degradation
CC       by both the lysosomal and proteasomal pathways. The E3 ubiquitin-
CC       protein ligase CBL significantly contributes to this ubiquitination.
CC       {ECO:0000269|PubMed:19880496}.
CC   -!- DISEASE: Congenital amegakaryocytic thrombocytopenia (CAMT)
CC       [MIM:604498]: Disease characterized by isolated thrombocytopenia and
CC       megakaryocytopenia with no physical anomalies.
CC       {ECO:0000269|PubMed:16470591, ECO:0000269|PubMed:25538044}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Thrombocythemia 2 (THCYT2) [MIM:601977]: A myeloproliferative
CC       disorder characterized by excessive platelet production, resulting in
CC       increased numbers of circulating platelets. It can be associated with
CC       spontaneous hemorrhages and thrombotic episodes.
CC       {ECO:0000269|PubMed:14764528, ECO:0000269|PubMed:19483125,
CC       ECO:0000269|PubMed:23441089, ECO:0000269|PubMed:25538044}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Myelofibrosis with myeloid metaplasia (MMM) [MIM:254450]: A
CC       chronic myeloproliferative disorder characterized by replacement of the
CC       bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia,
CC       leukoerythroblastosis and hepatosplenomegaly.
CC       {ECO:0000269|PubMed:16834459, ECO:0000269|PubMed:16868251}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 1
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-8 is the initiator.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M90102; AAA69971.1; -; mRNA.
DR   EMBL; M90103; AAA69972.1; -; mRNA.
DR   EMBL; U68162; AAB08424.1; -; Genomic_DNA.
DR   EMBL; U68159; AAB08424.1; JOINED; Genomic_DNA.
DR   EMBL; U68160; AAB08424.1; JOINED; Genomic_DNA.
DR   EMBL; U68161; AAB08424.1; JOINED; Genomic_DNA.
DR   EMBL; U68162; AAB08425.1; -; Genomic_DNA.
DR   EMBL; U68159; AAB08425.1; JOINED; Genomic_DNA.
DR   EMBL; U68160; AAB08425.1; JOINED; Genomic_DNA.
DR   EMBL; U68161; AAB08425.1; JOINED; Genomic_DNA.
DR   EMBL; AL139289; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07103.1; -; Genomic_DNA.
DR   CCDS; CCDS483.1; -. [P40238-1]
DR   PIR; A45266; A45266.
DR   PIR; B45266; B45266.
DR   RefSeq; NP_005364.1; NM_005373.2. [P40238-1]
DR   AlphaFoldDB; P40238; -.
DR   BioGRID; 110492; 44.
DR   DIP; DIP-5730N; -.
DR   ELM; P40238; -.
DR   IntAct; P40238; 2.
DR   STRING; 9606.ENSP00000361548; -.
DR   BindingDB; P40238; -.
DR   ChEMBL; CHEMBL1864; -.
DR   DrugBank; DB11995; Avatrombopag.
DR   DrugBank; DB06210; Eltrombopag.
DR   DrugBank; DB13125; Lusutrombopag.
DR   DrugBank; DB05332; Romiplostim.
DR   DrugBank; DB05930; SB-559448.
DR   DrugBank; DB06534; Thrombopoietin.
DR   DrugCentral; P40238; -.
DR   GuidetoPHARMACOLOGY; 1722; -.
DR   GlyConnect; 1803; 1 N-Linked glycan (1 site).
DR   GlyCosmos; P40238; 4 sites, 1 glycan.
DR   GlyGen; P40238; 4 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; P40238; -.
DR   PhosphoSitePlus; P40238; -.
DR   BioMuta; MPL; -.
DR   DMDM; 730980; -.
DR   MassIVE; P40238; -.
DR   PaxDb; P40238; -.
DR   PeptideAtlas; P40238; -.
DR   ProteomicsDB; 55354; -. [P40238-1]
DR   ProteomicsDB; 55355; -. [P40238-2]
DR   ABCD; P40238; 28 sequenced antibodies.
DR   Antibodypedia; 2379; 409 antibodies from 31 providers.
DR   DNASU; 4352; -.
DR   Ensembl; ENST00000372470.9; ENSP00000361548.3; ENSG00000117400.18. [P40238-1]
DR   GeneID; 4352; -.
DR   KEGG; hsa:4352; -.
DR   MANE-Select; ENST00000372470.9; ENSP00000361548.3; NM_005373.3; NP_005364.1.
DR   UCSC; uc001ciw.4; human. [P40238-1]
DR   AGR; HGNC:7217; -.
DR   CTD; 4352; -.
DR   DisGeNET; 4352; -.
DR   GeneCards; MPL; -.
DR   HGNC; HGNC:7217; MPL.
DR   HPA; ENSG00000117400; Low tissue specificity.
DR   MalaCards; MPL; -.
DR   MIM; 159530; gene.
DR   MIM; 254450; phenotype.
DR   MIM; 601977; phenotype.
DR   MIM; 604498; phenotype.
DR   neXtProt; NX_P40238; -.
DR   OpenTargets; ENSG00000117400; -.
DR   Orphanet; 3319; Congenital amegakaryocytic thrombocytopenia.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 71493; Familial thrombocytosis.
DR   Orphanet; 397692; Hereditary isolated aplastic anemia.
DR   Orphanet; 729; Polycythemia vera.
DR   Orphanet; 824; Primary myelofibrosis.
DR   PharmGKB; PA30923; -.
DR   VEuPathDB; HostDB:ENSG00000117400; -.
DR   eggNOG; ENOG502RYN1; Eukaryota.
DR   GeneTree; ENSGT00940000161225; -.
DR   HOGENOM; CLU_029931_1_0_1; -.
DR   InParanoid; P40238; -.
DR   OMA; IWEKCEE; -.
DR   OrthoDB; 5297263at2759; -.
DR   PhylomeDB; P40238; -.
DR   TreeFam; TF336573; -.
DR   PathwayCommons; P40238; -.
DR   Reactome; R-HSA-76009; Platelet Aggregation (Plug Formation).
DR   SignaLink; P40238; -.
DR   SIGNOR; P40238; -.
DR   BioGRID-ORCS; 4352; 15 hits in 1152 CRISPR screens.
DR   ChiTaRS; MPL; human.
DR   GeneWiki; Thrombopoietin_receptor; -.
DR   GenomeRNAi; 4352; -.
DR   Pharos; P40238; Tclin.
DR   PRO; PR:P40238; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P40238; protein.
DR   Bgee; ENSG00000117400; Expressed in mononuclear cell and 98 other tissues.
DR   ExpressionAtlas; P40238; baseline and differential.
DR   Genevisible; P40238; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0038164; F:thrombopoietin receptor activity; IMP:UniProtKB.
DR   GO; GO:1990960; P:basophil homeostasis; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:1990959; P:eosinophil homeostasis; IEA:Ensembl.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IBA:GO_Central.
DR   GO; GO:0035702; P:monocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0001780; P:neutrophil homeostasis; IEA:Ensembl.
DR   GO; GO:0070527; P:platelet aggregation; IEA:Ensembl.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IEA:Ensembl.
DR   GO; GO:1905221; P:positive regulation of platelet formation; IEA:Ensembl.
DR   GO; GO:0038163; P:thrombopoietin-mediated signaling pathway; IBA:GO_Central.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 4.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR015152; Growth/epo_recpt_lig-bind.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003528; Long_hematopoietin_rcpt_CS.
DR   PANTHER; PTHR23037; CYTOKINE RECEPTOR; 1.
DR   PANTHER; PTHR23037:SF28; ERYTHROPOIETIN RECEPTOR; 1.
DR   Pfam; PF09067; EpoR_lig-bind; 1.
DR   Pfam; PF00041; fn3; 1.
DR   SMART; SM00060; FN3; 2.
DR   SUPFAM; SSF49265; Fibronectin type III; 3.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disease variant; Disulfide bond;
KW   Glycoprotein; Golgi apparatus; Isopeptide bond; Membrane; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..635
FT                   /note="Thrombopoietin receptor"
FT                   /id="PRO_0000010987"
FT   TOPO_DOM        26..491
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        492..513
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        514..635
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          172..281
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          392..486
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   REGION          205..232
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           474..478
FT                   /note="WSXWS motif"
FT   MOTIF           528..536
FT                   /note="Box 1 motif"
FT   CARBOHYD        117
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        298
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        358
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        40..50
FT                   /evidence="ECO:0000250"
FT   DISULFID        77..93
FT                   /evidence="ECO:0000250"
FT   DISULFID        291..301
FT                   /evidence="ECO:0000250"
FT   DISULFID        323..334
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        553
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19880496"
FT   CROSSLNK        573
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT   VAR_SEQ         523..579
FT                   /note="RLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS
FT                   SERTP -> YRPRQAGDWRWTRWSRTCKQAFLVRSVTPDLRPPPVRTYGFALPARHLWD
FT                   SPRLLTL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1608974"
FT                   /id="VSP_001734"
FT   VAR_SEQ         580..635
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1608974"
FT                   /id="VSP_001735"
FT   VARIANT         39
FT                   /note="K -> N (associated with thrombocytosis; results in
FT                   altered MPL expression; dbSNP:rs17292650)"
FT                   /evidence="ECO:0000269|PubMed:15269348"
FT                   /id="VAR_049173"
FT   VARIANT         58
FT                   /note="A -> V (in dbSNP:rs6087)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_011988"
FT   VARIANT         102
FT                   /note="R -> C (in CAMT; dbSNP:rs763568293)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073030"
FT   VARIANT         102
FT                   /note="R -> P (in CAMT; loss of function; loss of membrane
FT                   localization, impaired glycosylation; dbSNP:rs28928907)"
FT                   /evidence="ECO:0000269|PubMed:16470591,
FT                   ECO:0000269|PubMed:25538044"
FT                   /id="VAR_073031"
FT   VARIANT         104
FT                   /note="F -> S (in CAMT; loss of function;
FT                   dbSNP:rs1196161699)"
FT                   /evidence="ECO:0000269|PubMed:16470591,
FT                   ECO:0000269|PubMed:25538044"
FT                   /id="VAR_073032"
FT   VARIANT         106
FT                   /note="P -> L (in THCYT2; gain of function; loss of
FT                   membrane localization, impaired glycosylation;
FT                   dbSNP:rs750046020)"
FT                   /evidence="ECO:0000269|PubMed:25538044"
FT                   /id="VAR_073033"
FT   VARIANT         114
FT                   /note="V -> M (in dbSNP:rs12731981)"
FT                   /id="VAR_049174"
FT   VARIANT         136
FT                   /note="P -> L (in CAMT; dbSNP:rs764904424)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073034"
FT   VARIANT         154
FT                   /note="W -> R (in CAMT; dbSNP:rs758428763)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073035"
FT   VARIANT         168
FT                   /note="E -> K (in dbSNP:rs6088)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_011989"
FT   VARIANT         257
FT                   /note="R -> L (in CAMT)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073036"
FT   VARIANT         275
FT                   /note="P -> T (in CAMT; dbSNP:rs28928908)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073037"
FT   VARIANT         435
FT                   /note="W -> C (in CAMT; dbSNP:rs1006158872)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073038"
FT   VARIANT         505
FT                   /note="S -> N (in THCYT2; activating mutation; induces MPL
FT                   autonomous dimerization and signal activation in the
FT                   absence of the ligand; dbSNP:rs121913614)"
FT                   /evidence="ECO:0000269|PubMed:14764528,
FT                   ECO:0000269|PubMed:19483125"
FT                   /id="VAR_067559"
FT   VARIANT         515
FT                   /note="W -> K (in MMM; somatic mutation; requires 2
FT                   nucleotide substitutions; dbSNP:rs121913616)"
FT                   /evidence="ECO:0000269|PubMed:16868251"
FT                   /id="VAR_067560"
FT   VARIANT         515
FT                   /note="W -> L (in THCYT2 and MMM; somatic mutation in
FT                   myelofibrosis with myeloid metaplasia; results in
FT                   cytokine-independent growth and thrombopoietin
FT                   hypersensitivity; results in constitutive activation of
FT                   JAK-STAT signaling pathway; dbSNP:rs121913615)"
FT                   /evidence="ECO:0000269|PubMed:16834459,
FT                   ECO:0000269|PubMed:23441089"
FT                   /id="VAR_067561"
FT   VARIANT         594
FT                   /note="L -> W (in CAMT; dbSNP:rs1448812001)"
FT                   /evidence="ECO:0000269|PubMed:16470591"
FT                   /id="VAR_073039"
SQ   SEQUENCE   635 AA;  71245 MW;  D25D8D8959359DDC CRC64;
     MPSWALFMVT SCLLLAPQNL AQVSSQDVSL LASDSEPLKC FSRTFEDLTC FWDEEEAAPS
     GTYQLLYAYP REKPRACPLS SQSMPHFGTR YVCQFPDQEE VRLFFPLHLW VKNVFLNQTR
     TQRVLFVDSV GLPAPPSIIK AMGGSQPGEL QISWEEPAPE ISDFLRYELR YGPRDPKNST
     GPTVIQLIAT ETCCPALQRP HSASALDQSP CAQPTMPWQD GPKQTSPSRE ASALTAEGGS
     CLISGLQPGN SYWLQLRSEP DGISLGGSWG SWSLPVTVDL PGDAVALGLQ CFTLDLKNVT
     CQWQQQDHAS SQGFFYHSRA RCCPRDRYPI WENCEEEEKT NPGLQTPQFS RCHFKSRNDS
     IIHILVEVTT APGTVHSYLG SPFWIHQAVR LPTPNLHWRE ISSGHLELEW QHPSSWAAQE
     TCYQLRYTGE GHQDWKVLEP PLGARGGTLE LRPRSRYRLQ LRARLNGPTY QGPWSSWSDP
     TRVETATETA WISLVTALHL VLGLSAVLGL LLLRWQFPAH YRRLRHALWP SLPDLHRVLG
     QYLRDTAALS PPKATVSDTC EEVEPSLLEI LPKSSERTPL PLCSSQAQMD YRRLQPSCLG
     TMPLSVCPPM AESGSCCTTH IANHSYLPLS YWQQP
//
